Literature DB >> 6972094

Positron computed tomography studies of cerebral glucose metabolism in man: theory and application in nuclear medicine.

M E Phelps.   

Abstract

The capability of positron computed tomography (PCT) to delineate the substructures of the brain and its facility for accurately measuring the local tissue radioactivity concentration allow the application of tracer kinetic models for the study of local cerebral function in man. This principle and an adaptation of the 14C-deoxyglucose (DG) model of Sokoloff et al. with 18F-2-fluoro-deoxy-D-glucose (FDG) is being used at UCLA. Brookhaven National Laboratory, University of Pennsylvania, NIH, and the Massachusetts General Hospital to determine the local cerebral glucose metabolic rate (LCMRGIc) in normal man at rest and during sensory activation and the changes that occur in patients with a variety of cerebral disorders. Kinetic studies with PCT have been employed to measure the rate constants of the model in different gray and white matter structures of the brain in both normal and ischemic states. The precision of the method in normals has been shown to be about +/- 5% for 1.5-2.0 sq cm regions of the brain. Studies in normals have yielded values for hemispheric CMRGIc that are in agreement with measurement using the Kety-Schmidt technique and LCMRGIc values in agreement with values in monkeys using DG autoradiography. Studies in volunteers subjected to visual and auditory stimulation are demonstrating the potential of this technique for investigating the human brain's response to different stimuli. STudies in patients with stroke show excellent correlation between the degree, extent, and particular structures involved and the clinical symptoms. The method consistently detected hypometabolism in cortical, thalamic, and striatal tissues that were dysfunctional due to deactivation or damage but which appeared normal on x-ray CT. Studies in patients with partial epilepsy have shown hypometabolic zones that highly correlated anatomically with interictal EEG spike foci and were associated with normal x-ray CT studies in 77% of the patients studied. The studies on epilepsy at UCLA have resulted in the integration of the LCMRGIc study into the clinical workup of patients with partial epilepsy that are candidates for surgical resection of their epileptogenic focus (effective June 1979). Studies on Huntington's chorea, Parkinson's disease, aphasia, dementia, schizophrenia, and tumors are in early stage of investigation but also are providing exciting new results. Further studies are needed to determine the role of the local function information obtained with the PCT-FDG method in elucidating the basic mechanism and the potential to aid in improving the approach to medical therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6972094     DOI: 10.1016/s0001-2998(81)80051-7

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  12 in total

Review 1.  PET/CT: a new imaging technology in nuclear medicine.

Authors:  Heiko Schöder; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-05       Impact factor: 9.236

Review 2.  The sweet spot: FDG and other 2-carbon glucose analogs for multi-modal metabolic imaging of tumor metabolism.

Authors:  Benjamin L Cox; Thomas R Mackie; Kevin W Eliceiri
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-12-15

Review 3.  Positron emission tomography.

Authors:  Y L Yamamoto; C J Thompson; M Diksic; E Meyer; W H Feindel
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

4.  Positron emission tomography (PET).

Authors:  M M Ter-Pogossian
Journal:  J Med Syst       Date:  1982-12       Impact factor: 4.460

Review 5.  Consensus statement on current and emerging methods for the diagnosis and evaluation of cerebrovascular disease.

Authors:  Manus J Donahue; Eric Achten; Petrice M Cogswell; Frank-Erik De Leeuw; Colin P Derdeyn; Rick M Dijkhuizen; Audrey P Fan; Rashid Ghaznawi; Jeremy J Heit; M Arfan Ikram; Peter Jezzard; Lori C Jordan; Eric Jouvent; Linda Knutsson; Richard Leigh; David S Liebeskind; Weili Lin; Thomas W Okell; Adnan I Qureshi; Charlotte J Stagg; Matthias Jp van Osch; Peter Cm van Zijl; Jennifer M Watchmaker; Max Wintermark; Ona Wu; Greg Zaharchuk; Jinyuan Zhou; Jeroen Hendrikse
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-17       Impact factor: 6.200

6.  Spatiotemporal uptake characteristics of [18]F-2-fluoro-2-deoxy-D-glucose in a rat middle cerebral artery occlusion model.

Authors:  Hong Yuan; Jonathan E Frank; Yonglong Hong; Hongyu An; Cihat Eldeniz; Jingxin Nie; Adomas Bunevicius; Dinggang Shen; Weili Lin
Journal:  Stroke       Date:  2013-06-06       Impact factor: 7.914

7.  Dynamic PET denoising with HYPR processing.

Authors:  Bradley T Christian; Nicholas T Vandehey; John M Floberg; Charles A Mistretta
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

Review 8.  PET in clinical oncology.

Authors:  R A Hawkins; M E Phelps
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

Review 9.  The potential roles of 18F-FDG-PET in management of acute stroke patients.

Authors:  Adomas Bunevicius; Hong Yuan; Weili Lin
Journal:  Biomed Res Int       Date:  2013-05-15       Impact factor: 3.411

10.  Cerebral blood flow and glucose metabolism measured with positron emission tomography are decreased in human type 1 diabetes.

Authors:  Larissa W van Golen; Marc C Huisman; Richard G Ijzerman; Nikie J Hoetjes; Lothar A Schwarte; Adriaan A Lammertsma; Michaela Diamant
Journal:  Diabetes       Date:  2013-03-25       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.